Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | SORD | Q00796 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201069 | 0.94 | CHRNA7 (0.54) | LMNASMN1; SMN2SORDHTTMAPT | |
| SCHEMBL5021493 | 0.87 | ELANE (0.61) | LMNASMN1; SMN2SORDHTTMAPT | |
| SCHEMBL31472604 | 0.87 | ELANE (0.61) | LMNASMN1; SMN2SORDHTTMAPT | |
| SCHEMBL30903262 | 0.87 | ELANE (0.57) | LMNASMN1; SMN2SORDHTTMAPT | |
| SCHEMBL2624458 | 0.85 | SORD (0.58) | LMNASMN1; SMN2SORDHTTMAPT | |
| SCHEMBL5021503 | 0.85 | ELANE (0.62) | LMNASMN1; SMN2SORDHTTMAPT | |
| SCHEMBL1981175 | 0.85 | ELANE (0.62) | LMNASMN1; SMN2SORDHTTMAPT | |
| SCHEMBL3072495 | 0.80 | PIK3CG (0.44) | HCRTR1HCRTR2 | |
| SCHEMBL30582934 | 0.80 | LMNA (0.50) | LMNASMN1; SMN2SORDHTTMAPT | |
| SCHEMBL1713373 | 0.79 | SORD (0.55) | LMNASMN1; SMN2SORDHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725538-B1 | PYRIDAZINONE UREAS AS ANTAGONISTS OF A4 INTEGRINS | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-29 | — | — | EP | claimed |
| US-20050209232-A1 | Pyridazinone ureas as antagonists of alpha4 integrins | JANSSEN PHARMACEUTICA,N.V. (BE) | 2005-09-22 | — | — | US | claimed |
| US-20230033021-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR | GLAS USA LLC | 2023-02-02 | — | — | US | disclosed |
| EP-1725538-B1 | PYRIDAZINONE UREAS AS ANTAGONISTS OF A4 INTEGRINS | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-29 | — | — | EP | disclosed |
| US-20050209232-A1 | Pyridazinone ureas as antagonists of alpha4 integrins | JANSSEN PHARMACEUTICA,N.V. (BE) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230033021-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR | ITGAL, ITGB2, ITGB1 | LMNA 3577/4885SMN1; SMN2 2275/4885SORD 2287/4885 |
| US-20050209232-A1 | Pyridazinone ureas as antagonists of alpha4 integrins | ITGA4, ITGB4, ITGB7 | LMNA 1659/4885SMN1; SMN2 3062/4885SORD 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.